| Neutrophil elastase inhibitor (ONO-5046-Na) inhibits the growth of human lung cancer cell lines transplanted into severe combined immunodeficiency (scid) mice. | |
| | |
MedLine Citation:
|
PMID: 9344234 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
We examined the in vivo effects of ONO-5046xNa, a specific neutrophil elastase (NE) inhibitor, on the growth of 2 non-small cell lung cancer cell lines, EBC-1 and PC-3, transplanted into severe combined immunodeficiency (scid) mice. The daily intraperitoneal injection of ONO-5046xNa (50 mg/kg/day) completely suppressed the tumor growth in EBC-1, a human squamous carcinoma cell line which produces immunoreactive NE. By contrast, in PC-3, a human adenocarcinoma cell line which is unable to produce immunoreactive NE, the ONO-5046xNa treatment caused delayed growth of the tumor. These findings suggest that ONO-5046xNa may have a clinical role in preventing the growth of human non-small cell lung cancer. |
| | |
Authors:
|
M Inada; J Yamashita; M Ogawa |
Related Documents
:
|
21781444 - Analysis of mgmt promoter methylation status on intraoperative fresh tissue section fro... 17543294 - Pre- and post-initiation chemoprevention activity of 2-alkyl/aryl selenazolidine-4(r)-c... 3722864 - Effect of betamethasone in lungs of mice treated with lymphocytosis-promoting factor of... 1554414 - Multiple molecular alterations in mouse lung tumors. 23128494 - B7-h3 expression in ductal and lobular breast cancer and its association with il-10. 10404094 - Genomic instability and alterations in apc, mcc and dcc in hong kong patients with colo... |
Publication Detail:
|
Type: Comparative Study; Journal Article |
Journal Detail:
|
Title: Research communications in molecular pathology and pharmacology Volume: 97 ISSN: 1078-0297 ISO Abbreviation: Res. Commun. Mol. Pathol. Pharmacol. Publication Date: 1997 Aug |
Date Detail:
|
Created Date: 1997-11-17 Completed Date: 1997-11-17 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9437512 Medline TA: Res Commun Mol Pathol Pharmacol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 229-32 Citation Subset: IM |
Affiliation:
|
Department of Surgery II, Kumamoto University School of Medicine, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adenocarcinoma
/
drug therapy*,
pathology Animals Antineoplastic Agents / administration & dosage, pharmacology* Carcinoma, Non-Small-Cell Lung / drug therapy*, pathology Carcinoma, Squamous Cell / drug therapy*, pathology Cell Division / drug effects Female Glycine / administration & dosage, analogs & derivatives*, pharmacology Humans Leukocyte Elastase / antagonists & inhibitors* Lung Neoplasms / drug therapy*, pathology Mice Mice, SCID Neutrophils / enzymology Serine Proteinase Inhibitors / administration & dosage, pharmacology* Sulfonamides / administration & dosage, pharmacology* Tumor Cells, Cultured |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Serine Proteinase Inhibitors; 0/Sulfonamides; 127373-66-4/ONO 5046; 56-40-6/Glycine; EC 3.4.21.37/Leukocyte Elastase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Induction of differentiation of U-937 cells by 2-chloro-3-amino-1,4-naphthoquinone.
Next Document: Cadmium and/or selenium effects on guinea pig lung PGE2, TXB2 and LTC4.